Table 1. Study cohort.
| total patients n=211 |
Group I * n=51 |
Group II * n=115 |
Group III * n= 45 |
P-value | |
|---|---|---|---|---|---|
| Patient Age: median (range) | 43.1(18.8, 68.8) | 44.8 (19.5, 67.6) | 42.2 (18.8, 64.8) | 41.9 (20.7, 68.8) | 0.27a |
| Donor Age: median (range) | 42.7 (15.2, 71.4) | 43.0 (18.4, 64.4) | 42.5 (19.0, 71.4) | 39.5 (15.2, 60.2) | 0.10a |
| Donor Type number (%) | |||||
| Sibling | 141 (67%) | 39 (76%) | 73 (63%) | 29 (64%) | 0.25a |
| URD | 70 (33%) | 12 (24%) | 42 (37%) | 16 (36%) | |
| Hematopoietic Progenitor Cell Source: number (%) | |||||
| Bone Marrow | 32 (15%) | 3 (6%) | 20 (17%) | 9 (20%) | 0.09a |
| Peripheral Blood | 179 (85%) | 48 (94%) | 95 (83%) | 36 (80%) | |
| Diagnosis: number (%) | |||||
| Lymphoid Malignancy | 82 (39%) | 18 (35%) | 45 (39%) | 19 (42%) | 0.22a |
| Myeloid Malignancy | 118 (56%) | 30 (59%) | 67 (58%) | 21 (47%) | |
| Other | 11 (5%) | 3 (6%) | 3 (3%) | 5 (11%) | |
| Conditioning Regimen: number (%) | |||||
| Myeloablative: | 134 (64%) | 30 (59%) | 75 (65%) | 29 (64%) | 0.76a |
| Nonmyeloablative: | 77(36%) | 21 (41%) | 40 (35%) | 16 (36%) | |
| CMV Serology: number | |||||
| unknown | 2 | 0 | 1 | 1 | 0.53a |
| D+/R+ | 133 (64%) | 33 (65%) | 72 (63%) | 28 (64%) | |
| D+/R- | 25 (12%) | 9 (17%) | 11 (10%) | 5 (11%) | |
| D-/R+ | 51 (24%) | 9 (17%) | 31 (27%) | 11 (25%) | |
| Acute GVHD : number (%) | |||||
| unknown | 1 | 0 | 1 | 0 | 0.97b |
| None | 58 (28%) | 14 (27%) | 31 (27%) | 13 (29%) | |
| Grade 1 | 24 (11) | 5 (10%) | 14 (12%) | 5 (11%) | |
| Grade 2 | 83 (39%) | 23 (45%) | 42 (37%) | 18 (40%) | |
| Grade 3 | 37 (18%) | 8 (16%) | 21 (19%) | 8 (18%) | |
| Grade 4 | 8 (4%) | 1 (2%) | 6 (5%) | 1 (2%) | |
| Chronic GVHD: number (%) | |||||
| unknown | 4 | 1 | 2 | 1 | 0.94b |
| None | 48 (23%) | 12 (24%) | 24 (21%) | 12 (27%) | |
| Yes: limited | 27 (13%) | 6 (12%) | 16 (14%) | 5 (11%) | |
| Extensive | 132 (64%) | 32(64%) | 73 (68%) | 27 (61%) | |
| Steroids | |||||
| none | 52 (25%) | 15 (29%) | 25 (21%) | 12 (27%) | 0.4b |
| 0<1mg/kg | 99 (47%) | 19 (37%) | 56 (49%) | 24 (53%) | |
| >1mg/kg | 60 (28%) | 17 (33%) | 34 (30%) | 9 (20%) | |
| Overall survival | 0.72 (0.57,0.82) | 0.77(0.68,0.84) | 0.84(0.70,0.92) | 0.2c | |
*
Group I: no 2DS2 –no 2DS4; Group II: 2DS2 or 2DS4; Group III: 2DS2 and 2DS4 or ≥ 5aKIR
a
Fisher's exact test/Kruskal-Wallis test
b
Pearson Chi-square test
c
Log-rank test